Waters Corporation 10-Q Summary: Period Ended June 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, and the six-month period ended on the same date. Waters Corporation is the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, chromatography columns, and related services. Through subsidiaries Micromass Limited and TA Instruments, Inc., the Company also leads in mass spectrometry and thermal analysis. For financial reporting purposes, these three operating segments are aggregated into a single reporting segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 | Six Months Ended June 30, 2001 |
|---|---|---|
| Net Sales | $206.8 million | $407.8 million |
| Gross Profit | $131.3 million (63.5% margin) | $259.0 million (63.5% margin) |
| Operating Income | $50.6 million | $99.6 million |
| Net Income | $39.3 million | $77.7 million |
| Diluted EPS | $0.29 | $0.56 |
| Cash from Operations | N/A | $78.1 million |
| Cash and Equivalents (Ending) | $134.5 million | |
| Total Debt (Notes Payable) | $2.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% for the quarter and 8% for the six-month period compared to 2000. Excluding the adverse impact of a stronger U.S. dollar, sales growth was 9% for the quarter and 12% for the period.
- Profitability: Operating income decreased 3% for the quarter ($50.6M vs. $52.3M) due to slower sales growth in mass spectrometry and increased selling, general, and administrative (SG&A) expenses. However, operating income increased 6% for the six-month period ($99.6M vs. $93.5M) driven by overall sales growth and productivity improvements.
- Expense Trends: SG&A expenses rose 10% year-over-year for both the quarter and period, primarily due to increased headcount to support sales levels. R&D expenses increased 11% for the quarter and 9% for the period.
- Working Capital: Cash flow from operations was impacted by a $24.1 million increase in inventory levels. Accounts receivable decreased slightly, while accounts payable increased.
- Interest Income: Net interest income improved significantly to $1.2 million for the quarter and $2.6 million for the period, reversing net interest expenses of $0.3 million and $1.0 million in the prior year periods.
Outlook, Risks, and Unusual Items
- Market Conditions: Sales growth slowed in the mass spectrometry product line due to reduced order closure rates with large pharmaceutical accounts. Thermal analysis sales were slightly down due to a weak industrial chemical customer base. HPLC sales continued to grow in the low double digits.
- Currency Impact: A stronger U.S. dollar reduced reported sales growth by four percentage points in the quarter, primarily due to the weakening of the euro and Japanese yen. The Company uses debt swaps and forward contracts to hedge foreign currency exposure.
- Accounting Changes: The Company adopted SFAS 133 (Derivatives and Hedging) effective January 1, 2001, with no material impact. A cumulative effect of a prior accounting change (SAB 101) in 2000 resulted in a $10.8 million charge in the prior year, which is not present in the current period.
- Liquidity: Management believes existing cash balances ($134.5 million) and available borrowings are sufficient to fund future working capital and capital spending. No dividends are planned.
- Risks: Forward-looking statements are subject to risks including changes in the analytical instrument marketplace, competitive pricing, and the ability to generate sales from new product introductions.
Investor Verification Checklist
- Verify the sustainability of HPLC sales growth given the slowdown in mass spectrometry and thermal analysis segments.
- Monitor inventory levels, which increased by $24.1 million in the first half of 2001, to ensure they align with future demand.
- Assess the impact of foreign currency fluctuations on future earnings, as the strong dollar negatively affected reported sales growth.
- Review the effectiveness of SG&A expense controls as headcount increases to support sales.
- Confirm the status of the amendment to increase authorized common stock from 200 million to 400 million shares, which was approved by shareholders in May 2001.